Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis
Conditions
Interventions
Apremilast 20mg
Apremilast 30mg
+2 more
Locations
92
United States
Achieve Clinical Research LLC
Birmingham, Alabama, United States
Arizona Research Center
Phoenix, Arizona, United States
UCSD-Thornton Hospital
La Jolla, California, United States
Stanford University Medical Center
Palo Alto, California, United States
Inland Rheumatology Clinical Trials
Upland, California, United States
Arthritis and Rheumatic Disease Specialties
Aventura, Florida, United States
Start Date
June 2, 2010
Primary Completion Date
April 27, 2012
Completion Date
October 27, 2016
Last Updated
June 19, 2020
NCT07295509
NCT07286058
NCT06100744
NCT04402086
NCT06888193
NCT07315061
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions